Recursion Pharmaceuticals, Inc.

RXRX

US75629V1044

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 14:22:32 2025-06-16 EDT			5-day change	1st Jan Change
5.065 ^USD	+2.95%		-5.59%	-25.00%

06-10	Recursion Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 03:20 PM
06-10	Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	MT

Recursion to lay off 20% of workforce amid biotech funding woes

Published on 2025-06-10 at 07:46

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 03:20 PM	06-10
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	06-10	MT
Wall St set to open slightly higher as US-China trade talks grab focus	06-10	RE
Recursion Cuts 20% of Workforce, Extends Cash Runway to Late 2027	06-10	MT
Recursion to lay off 20% of workforce amid biotech funding woes	06-10	RE
Wall Street futures mixed as US-China trade talks grab focus	06-10	RE
Recursion Pharmaceuticals Announces Personnel And Infrastructure Reduction - SEC Filing	06-10	RE
Recursion to lay off 20% of workforce, narrows focus amid biotech downturn	06-10	RE
MIT and Recursion Release Boltz-2: Next Generation Ai Model to Predict Binding Affinity At Unprecedented Speed, Scale, and Accuracy	06-06	CI
Recursion Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 05, 2025	06-04
Recursion Pharmaceuticals, Inc. Presents at 53rd Annual JPMorgan Global Technology, Media and Communications Conference, May-15-2025 10:00 AM	05-15
Recursion Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10:00 AM	05-13
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Investors Brace for Fed Decision	05-05	MT
Recursion Pharmaceuticals Q1 Loss Widens, Revenue Increases	05-05	MT
Earnings Flash (RXRX) Recursion Pharmaceuticals Posts Q1 Revenue $14.7M, vs. FactSet Est of $15M	05-05	MT
Earnings Flash (RXRX) Recursion Pharmaceuticals Posts Q1 Net Loss $0.50 a Share, vs. FactSet Est of $0.39 Loss	05-05	MT
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-05	CI
Recursion Pharmaceuticals Reports Promising Early Results for Familial Adenomatous Polyposis Drug Trial	05-05	MT
Recursion Announces Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis Demonstrates Reduced Polyp Burden	05-04	CI
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 Trial of REC-4881 in FAP at Digestive Disease Week 2025	04-22	CI
Recursion Pharmaceuticals Licenses HealthVerity's Real-World Data	04-16	MT
Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World Data	04-16	RE
Healthverity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data	04-16	CI
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries	04-09	CI
Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment	04-08	MT

Chart Recursion Pharmaceuticals, Inc.

Duration

Period

RXRX: Dynamic Chart

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.

Employees

800

Sector

Biotechnology & Medical Research

Calendar

06-18 - Annual General Meeting

More about the company